



Press release 2016-07-01

## Leading cancer centers in China to be equipped with C-RAD technology

**C-RAD has received an order from its Chinese distributor for Catalyst™ and Sentinel™ systems, to be installed at leading cancer centers in China. The order has a total value of approximately 7.6 MSEK.**

The Catalyst™ systems will be installed on Varian True Beam™ and Elekta Versa HD™ linear accelerators. The systems are delivered in different software configurations containing software modules for Patient Setup and Positioning and Respiratory Gating, including respective interfaces for communication with the treatment system. The interfaces allow a seamless integration for patient synchronization and an automated patient setup and beam control to treat tumors that may be moving due to respiratory motion.

The delivery and installation of the systems is expected to occur over the next 12 months.

C-RAD has its Asian headquarters in Shanghai. C-RAD is working through its own sales organization and a distributor, Beijing HGPT Technology & Trade Co., for sales and marketing of the C-RAD and Cyrpa product lines. Installation, clinical application and service are provided by engineers from the distributor as well as C-RAD's own personnel. The distributor has a sales organization with a strong presence in China's economically important regions.

In May C-RAD and Beijing HGPT co-hosted a clinical symposium in Shanghai. International and domestic speakers presented their clinical experiences and research results with the C-RAD systems. The symposium was attended by more than 100 customers.

“Since C-RAD received clearance for the Catalyst we started our marketing and promotion of the product,” says Mrs. Wen Bing, Chairman of Beijing HGPT Technology & Trade. “The Catalyst launch event here in Shanghai in the beginning of May was a big success. The interest from physicists and oncologists from leading cancer centers all over China led to exciting presentations and interesting talks as part of the Symposium. The first tenders, where Catalyst was part of our offering, led to the first orders we received. We are looking forward to support and grow the community of Catalyst users here in China.”

“This order underlines the strength of our presence in China,” says Tim Thurn, CEO of C-RAD. “The cooperation with our distributor for Sentinel, Catalyst and Cyrpa laser products is functioning very successfully. During the first quarter of this year we received the clearance to sell and promote Catalyst in China. The attendance at the symposium exceeded our expectations, which underscores the rapid growth of the Chinese healthcare market. We are continuously working on strengthening our presence on the important Chinese market.”

### *About C-RAD*

*C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD*



*Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 43. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit [www.c-rad.com](http://www.c-rad.com)*

**For further information:**

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email [investors@c-rad.com](mailto:investors@c-rad.com)

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).

